See more : Gores Metropoulos II, Inc. (GMIIW) Income Statement Analysis – Financial Results
Complete financial analysis of Sorrento Therapeutics, Inc. (SRNE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sorrento Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Avalon GloboCare Corp. (ALBT) Income Statement Analysis – Financial Results
- Solis Minerals Ltd. (SLMFF) Income Statement Analysis – Financial Results
- Walker Crips Group plc (WCW.L) Income Statement Analysis – Financial Results
- Athena Bitcoin Global (ABIT) Income Statement Analysis – Financial Results
- Independence Holdings Corp. (ACQR) Income Statement Analysis – Financial Results
Sorrento Therapeutics, Inc. (SRNE)
About Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 62.84M | 52.90M | 39.99M | 31.43M | 21.19M | 151.86M | 8.15M | 4.59M | 3.83M | 460.15K | 583.77K | 529.18K | 682.57K | 5.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 33.45M | 13.03M | 9.94M | 12.24M | 10.07M | 11.03M | 3.70M | 1.95M | 2.04M | 4.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 29.39M | 39.87M | 30.05M | 19.20M | 11.12M | 140.83M | 4.46M | 2.64M | 1.78M | 455.71K | 583.77K | 529.18K | 682.57K | 5.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 46.77% | 75.37% | 75.14% | 61.07% | 52.49% | 92.74% | 54.66% | 57.52% | 46.59% | 99.04% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 221.23M | 206.92M | 111.34M | 106.88M | 76.96M | 55.53M | 42.18M | 31.34M | 23.98M | 9.02M | 3.83M | 2.57M | 1.39M | 410.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 63.64M | 38.33M | 24.22M | 20.13M | 9.99M | 6.32M | 1.61M | 0.00 | 0.00 | 0.00 | 0.00 | 240.63K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.37M | -2.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 182.34M | 196.86M | 116.18M | 103.56M | 63.64M | 32.96M | 22.18M | 20.13M | 9.99M | 6.32M | 1.61M | 1.20M | 1.10M | 543.95K | 190.52K | 240.63K | 439.29K | 0.00 | 0.00 | 0.00 |
| Other Expenses | 130.14M | 4.14M | 4.05M | 3.94M | 3.01M | 2.61M | 845.00K | 1.16M | 2.35M | 804.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -308.03K | -763.00 | -763.00 |
| Operating Expenses | 533.70M | 407.92M | 231.57M | 214.38M | 140.60M | 88.49M | 64.35M | 52.63M | 36.32M | 16.14M | 5.44M | 3.77M | 2.49M | 954.12K | 190.52K | 240.63K | 439.29K | -308.03K | -763.00 | -763.00 |
| Cost & Expenses | 567.15M | 420.95M | 241.51M | 226.61M | 150.67M | 99.52M | 68.05M | 54.58M | 38.36M | 16.14M | 5.44M | 3.77M | 2.49M | 954.12K | 190.52K | 240.63K | 439.29K | -308.03K | -763.00 | -763.00 |
| Interest Income | 0.00 | 0.00 | 24.00K | 1.09M | 921.00K | 241.00K | 272.00K | 24.00K | 12.00K | 9.62K | 7.30K | 5.95K | 3.79K | 11.86K | 1.61K | 9.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.57M | 10.22M | 20.18M | 36.14M | 57.63M | 4.98M | 1.61M | 1.65M | 1.63M | 253.19K | 7.30K | 5.95K | 3.79K | 11.86K | 1.61K | 0.00 | 0.00 | 0.00 | 0.00 | 763.00 |
| Depreciation & Amortization | 13.25M | 16.32M | 14.71M | 15.04M | 9.05M | 7.08M | 2.89M | 2.37M | 3.18M | 1.29M | 293.30K | 159.22K | 23.41K | 2.76K | 3.23K | -29.99K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -539.93M | -435.99M | -275.69M | -308.40M | -147.10M | 27.38M | -60.34M | -9.74M | -31.55M | -20.37M | -4.55M | -3.08M | -1.78M | -939.51K | -187.29K | -270.62K | -439.29K | -308.03K | -763.00 | -763.00 |
| EBITDA Ratio | -859.22% | -724.81% | -479.85% | -582.53% | -568.22% | 39.13% | -699.37% | -119.28% | -824.73% | -4,426.33% | -778.50% | -580.39% | -260.95% | -17,137.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -504.32M | -368.05M | -201.53M | -195.18M | -129.48M | 52.34M | -59.90M | -74.01M | -34.74M | -21.67M | -4.85M | -3.24M | -1.81M | -954.12K | -190.52K | -240.63K | -439.29K | -308.03K | -763.00 | -763.00 |
| Operating Income Ratio | -802.55% | -695.68% | -503.99% | -620.97% | -610.94% | 34.46% | -734.76% | -1,612.31% | -908.29% | -4,708.85% | -831.25% | -612.72% | -265.49% | -17,626.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -57.43M | -94.48M | -66.06M | -100.18M | -63.36M | -10.02M | -4.94M | 36.23M | -1.62M | -6.23M | 7.30K | 5.95K | 3.79K | 11.86K | 0.00 | -30.00K | 0.00 | -308.03K | 0.00 | 0.00 |
| Income Before Tax | -561.75M | -462.53M | -310.58M | -359.58M | -213.78M | 15.32M | -64.83M | -13.76M | -36.36M | -21.91M | -4.85M | -3.24M | -1.81M | -942.27K | 0.00 | -270.63K | 0.00 | -616.06K | 0.00 | 0.00 |
| Income Before Tax Ratio | -893.95% | -874.28% | -776.72% | -1,143.98% | -1,008.73% | 10.09% | -795.30% | -299.78% | -950.56% | -4,761.79% | -830.00% | -611.60% | -264.94% | -17,407.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.42M | -33.52M | -2.01M | -473.00K | -6.27M | -36.04M | -896.00K | 36.31M | -1.70M | 9.62K | 14.60K | 11.90K | 7.57K | 23.71K | -1.61K | -9.00 | 439.29K | -308.03K | 763.00 | 763.00 |
| Net Income | -572.84M | -429.01M | -308.57M | -359.10M | -203.54M | 9.06M | -60.92M | -45.81M | -34.66M | -21.91M | -4.85M | -3.24M | -1.81M | -942.27K | -188.90K | -270.62K | -439.29K | -308.03K | -763.00 | -763.00 |
| Net Income Ratio | -911.60% | -810.93% | -771.69% | -1,142.48% | -960.41% | 5.97% | -747.34% | -998.06% | -906.07% | -4,761.79% | -830.00% | -611.60% | -264.94% | -17,407.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.37 | -1.46 | -1.34 | -2.56 | -1.92 | 0.13 | -1.21 | -1.24 | -1.30 | -1.46 | -0.42 | -0.33 | -0.20 | -0.15 | -0.50 | -1.05 | -15.46 | -10.84 | -0.03 | -0.03 |
| EPS Diluted | -1.37 | -1.46 | -1.34 | -2.56 | -1.92 | 0.13 | -1.21 | -1.24 | -1.30 | -1.46 | -0.42 | -0.33 | -0.20 | -0.15 | -0.50 | -1.05 | -15.46 | -10.84 | -0.03 | -0.03 |
| Weighted Avg Shares Out | 419.32M | 294.77M | 229.82M | 140.51M | 106.15M | 69.74M | 50.36M | 36.91M | 26.68M | 15.05M | 11.41M | 9.92M | 8.83M | 6.08M | 378.02K | 257.93K | 28.41K | 28.41K | 28.41K | 28.41K |
| Weighted Avg Shares Out (Dil) | 419.32M | 294.77M | 229.82M | 140.51M | 106.15M | 70.38M | 50.36M | 36.91M | 26.68M | 15.05M | 11.41M | 9.92M | 8.83M | 6.08M | 378.02K | 257.93K | 28.41K | 28.41K | 28.41K | 28.41K |
Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the ASCO 2023 Meeting
Why Sorrento Therapeutics Stock Crashed Today
The $75 Million Reason Sorrento (SRNE) Stock Is Moving Today
Penny Stocks To Buy? 7 To Watch Now After Big News
How to Stay Disciplined When Investing in Penny Stocks
Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case
Why Shares of Sorrento Therapeutics Are Up Today
Best Penny Stocks To Buy Now? 4 With Big News In February
Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)
How to Know When to Sell Penny Stocks
Source: https://incomestatements.info
Category: Stock Reports